Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516)

John Nemunaitis, John Cox, Sarah Hays, Wally Meyer, Richard Kebart, Nadine Ognoskie, Alice Courtney, Yaang Yu, Henrick Rasmussen, Alex Tong

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We determined the prognostic role of K-ras mutation in tumor tissue of patients with refractory colon cancer who received Marimastat (BB2516). DNA was extracted from paraffin-stored tumor tissue of 27 patients who previously failed 5-fluorouracil and were treated with BB2516. The presence of K-ras mutation was characterized by Polymerase Chain Reaction using ras- and p53- specific primers. ras and p53 oncoprotein expression was analyzed by an automated biotin-avidin immunoproxidase technique. Seventeen patients had a normal K-ras sequence and 10 patients had a K-ras mutation. Median survival of patients with a normal ras sequence was 330 days from the time of BB2516 treatment compared with 160 days for patients with a K-ras mutation (p = 0.0442, Wilcoxon; 0.0130 Log-Rank). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Abnormalities involving ras expression did not affect survival. By comparison, median survival for patients with p53 mutation or p53 overexpression was both 158 days after BB2516 treatment. Patients having both K-ras and p53 mutations had the poorest median survival of 113 days (p = 0.035). There is a suggestion by univariate analysis that the presence of a K-ras mutation may predict survival in patients with progressive colon cancer. Further assessment with larger patient numbers and multivariate analysis is indicated.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalCancer Investigation
Volume18
Issue number3
DOIs
StatePublished - Jan 1 2000

Fingerprint

Colonic Neoplasms
Mutation
Survival
Therapeutics
marimastat
Tumor Suppressor Protein p53
Neoplasms
Avidin
Biotin
Fluorouracil
Paraffin
Multivariate Analysis
Drug Therapy
Polymerase Chain Reaction
DNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516). / Nemunaitis, John; Cox, John; Hays, Sarah; Meyer, Wally; Kebart, Richard; Ognoskie, Nadine; Courtney, Alice; Yu, Yaang; Rasmussen, Henrick; Tong, Alex.

In: Cancer Investigation, Vol. 18, No. 3, 01.01.2000, p. 185-190.

Research output: Contribution to journalArticle

Nemunaitis, J, Cox, J, Hays, S, Meyer, W, Kebart, R, Ognoskie, N, Courtney, A, Yu, Y, Rasmussen, H & Tong, A 2000, 'Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516)', Cancer Investigation, vol. 18, no. 3, pp. 185-190. https://doi.org/10.3109/07357900009031822
Nemunaitis, John ; Cox, John ; Hays, Sarah ; Meyer, Wally ; Kebart, Richard ; Ognoskie, Nadine ; Courtney, Alice ; Yu, Yaang ; Rasmussen, Henrick ; Tong, Alex. / Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516). In: Cancer Investigation. 2000 ; Vol. 18, No. 3. pp. 185-190.
@article{4a5a3b1f138545f192754b46ead94c1e,
title = "Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516)",
abstract = "We determined the prognostic role of K-ras mutation in tumor tissue of patients with refractory colon cancer who received Marimastat (BB2516). DNA was extracted from paraffin-stored tumor tissue of 27 patients who previously failed 5-fluorouracil and were treated with BB2516. The presence of K-ras mutation was characterized by Polymerase Chain Reaction using ras- and p53- specific primers. ras and p53 oncoprotein expression was analyzed by an automated biotin-avidin immunoproxidase technique. Seventeen patients had a normal K-ras sequence and 10 patients had a K-ras mutation. Median survival of patients with a normal ras sequence was 330 days from the time of BB2516 treatment compared with 160 days for patients with a K-ras mutation (p = 0.0442, Wilcoxon; 0.0130 Log-Rank). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Abnormalities involving ras expression did not affect survival. By comparison, median survival for patients with p53 mutation or p53 overexpression was both 158 days after BB2516 treatment. Patients having both K-ras and p53 mutations had the poorest median survival of 113 days (p = 0.035). There is a suggestion by univariate analysis that the presence of a K-ras mutation may predict survival in patients with progressive colon cancer. Further assessment with larger patient numbers and multivariate analysis is indicated.",
author = "John Nemunaitis and John Cox and Sarah Hays and Wally Meyer and Richard Kebart and Nadine Ognoskie and Alice Courtney and Yaang Yu and Henrick Rasmussen and Alex Tong",
year = "2000",
month = "1",
day = "1",
doi = "10.3109/07357900009031822",
language = "English (US)",
volume = "18",
pages = "185--190",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516)

AU - Nemunaitis, John

AU - Cox, John

AU - Hays, Sarah

AU - Meyer, Wally

AU - Kebart, Richard

AU - Ognoskie, Nadine

AU - Courtney, Alice

AU - Yu, Yaang

AU - Rasmussen, Henrick

AU - Tong, Alex

PY - 2000/1/1

Y1 - 2000/1/1

N2 - We determined the prognostic role of K-ras mutation in tumor tissue of patients with refractory colon cancer who received Marimastat (BB2516). DNA was extracted from paraffin-stored tumor tissue of 27 patients who previously failed 5-fluorouracil and were treated with BB2516. The presence of K-ras mutation was characterized by Polymerase Chain Reaction using ras- and p53- specific primers. ras and p53 oncoprotein expression was analyzed by an automated biotin-avidin immunoproxidase technique. Seventeen patients had a normal K-ras sequence and 10 patients had a K-ras mutation. Median survival of patients with a normal ras sequence was 330 days from the time of BB2516 treatment compared with 160 days for patients with a K-ras mutation (p = 0.0442, Wilcoxon; 0.0130 Log-Rank). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Abnormalities involving ras expression did not affect survival. By comparison, median survival for patients with p53 mutation or p53 overexpression was both 158 days after BB2516 treatment. Patients having both K-ras and p53 mutations had the poorest median survival of 113 days (p = 0.035). There is a suggestion by univariate analysis that the presence of a K-ras mutation may predict survival in patients with progressive colon cancer. Further assessment with larger patient numbers and multivariate analysis is indicated.

AB - We determined the prognostic role of K-ras mutation in tumor tissue of patients with refractory colon cancer who received Marimastat (BB2516). DNA was extracted from paraffin-stored tumor tissue of 27 patients who previously failed 5-fluorouracil and were treated with BB2516. The presence of K-ras mutation was characterized by Polymerase Chain Reaction using ras- and p53- specific primers. ras and p53 oncoprotein expression was analyzed by an automated biotin-avidin immunoproxidase technique. Seventeen patients had a normal K-ras sequence and 10 patients had a K-ras mutation. Median survival of patients with a normal ras sequence was 330 days from the time of BB2516 treatment compared with 160 days for patients with a K-ras mutation (p = 0.0442, Wilcoxon; 0.0130 Log-Rank). No differences in age, sex, cancer stage, surgical treatment, or chemotherapy treatment were observed. Abnormalities involving ras expression did not affect survival. By comparison, median survival for patients with p53 mutation or p53 overexpression was both 158 days after BB2516 treatment. Patients having both K-ras and p53 mutations had the poorest median survival of 113 days (p = 0.035). There is a suggestion by univariate analysis that the presence of a K-ras mutation may predict survival in patients with progressive colon cancer. Further assessment with larger patient numbers and multivariate analysis is indicated.

UR - http://www.scopus.com/inward/record.url?scp=0034108378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034108378&partnerID=8YFLogxK

U2 - 10.3109/07357900009031822

DO - 10.3109/07357900009031822

M3 - Article

C2 - 10754986

AN - SCOPUS:0034108378

VL - 18

SP - 185

EP - 190

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 3

ER -